Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer, inflammatory, and metabolic diseases in North America, Europe, and Asia Pacific. Its programs under development pipeline include ARRY-403, a glucokinase activator for Type 2 diabetes, that is in a Phase 1 multiple ascending dose trial; ARRY-162, a MEK inhibitor for cancer that is in a Phase 1 trial; ARRY-380, an ErbB-2 inhibitor for breast cancer, which is in Phase 1 dose escalation trial; and ARRY-520, a KSP inhibitor that is in Phase 1 expansion trial in solid tumors and Phase 1/2 acute myeloid leukemia and multiple myeloma trials. The company's programs also comprise ARRY-614, a p38/Tie 2 dual inhibitor, which is in Phase 1 trial in myelodysplastic syndrome patients; ARRY-543, an ErbB family (ErbB-2/EGFR) inhibitor for solid tumors that is in Phase 1b combination trials; ARRY-797, a p38 inhibitor for subacute pain and cancer supportive care indications; and ARRY-300, an MEK that completed Phase 1 trial in healthy volunteers. It has collaborations with Celgene Corporation focusing on the discovery, development, and commercialization of novel therapeutics in cancer and inflammation; Genentech, Inc. to develop cancer programs; and AstraZeneca, PLC, which licensed the company's three MEK inhibitors for cancer, including AZD6244 (ARRY-886). The company was founded in 1998 and is headquartered in Boulder, Colorado.